Parkinson Therapy Breakthrough Fails to Lift Bayer’s Stock
25.09.2025 - 17:09:05 | boerse-global.de
Bayer shares experienced a decline on Wednesday, despite the company announcing a significant advancement in its Parkinson’s disease treatment program. The pharmaceutical and agricultural giant has dosed the first patient in a pivotal Phase III clinical trial for its promising cell therapy, Bemdaneprocel. This milestone, which follows a successful Phase I study, could substantially accelerate the path to market for this potential breakthrough treatment. A separate Phase II trial for an additional Parkinson’s gene therapy is also launching in Europe.
The lack of a positive market reaction highlights a clear disconnect between long-term research potential and immediate financial concerns. Investors appear to be focusing on pressing issues rather than future prospects. The therapy itself represents a novel approach, aiming... Read more...
So schätzen die Börsenprofis Parkinson Aktien ein!
Für. Immer. Kostenlos.
